BioVie Inc. (BIVI) should not have an enterprise value of $31 million. At that mark, the company is a sell. Other peers exhibiting a more advanced pipeline have a valuation close to that of BioVie Inc. Besides, the number of operating risks is elevated. The most worrying is that a significant competitor is challenging the most relevant patent owned by BIVI. Moreover, the company is a controlled entity, and the amount of related party transactions is very high.
Source: Prospectus
Source: Prospectus
Business And Intangible Assets
BioVie Inc. is a clinical-stage company focused